S H Thorne

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint Combining immune cell and viral therapy for the treatment of cancer
    S H Thorne
    Bio X Program, Molecular Imaging Program at Stanford MIPS and Department of Pediatrics, Stanford University, Stanford, CA, USA
    Cell Mol Life Sci 64:1449-51. 2007
  2. ncbi request reprint Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects
    Stephen H Thorne
    Department of Pediatrics and Bio X Program, Stanford University School of Medicine, Stanford, CA 94305 5427, USA
    Semin Oncol 32:537-48. 2005
  3. ncbi request reprint Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors
    Steve H Thorne
    Stanford University, Bio X Programme and Department of Pediatrics, Clark Center, California 94305, USA
    Expert Opin Biol Ther 7:41-51. 2007
  4. pmc Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
    Steve H Thorne
    Department of Pediatrics and Bio X Program, James H Clark Center, Stanford University School of Medicine, Stanford, California, USA
    J Clin Invest 117:3350-8. 2007
  5. pmc CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy
    Steve H Thorne
    Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA
    Mol Cancer Ther 8:333-41. 2009
  6. ncbi request reprint Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus
    Steve H Thorne
    Bio X Program, Dept of Pediatrics, School of Medicine, Stanford University, CA, USA
    Expert Opin Biol Ther 4:1307-21. 2004
  7. pmc Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killing
    Yoram Barak
    Department of Microbiology and Immunology, Sherman Fairchild Science Building, Stanford University School of Medicine, 299 Campus Drive, Stanford, CA 94305, USA
    BMC Cancer 10:146. 2010
  8. ncbi request reprint Synergistic antitumor effects of immune cell-viral biotherapy
    Steve H Thorne
    Departments of Pediatrics, Radiology, Microbiology, and Immunology Stanford University School of Medicine, Stanford, CA 94305, USA
    Science 311:1780-4. 2006
  9. ncbi request reprint Oncolytic vaccinia virus: from bedside to benchtop and back
    Steve H Thorne
    University of Pittsburgh Cancer Institute and Division of Surgical Oncology, Hillman Cancer Center, 5150 Centre Avenue, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Curr Opin Mol Ther 10:387-92. 2008
  10. ncbi request reprint Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University, Stanford, California, USA
    Clin Cancer Res 12:1859-67. 2006

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Combining immune cell and viral therapy for the treatment of cancer
    S H Thorne
    Bio X Program, Molecular Imaging Program at Stanford MIPS and Department of Pediatrics, Stanford University, Stanford, CA, USA
    Cell Mol Life Sci 64:1449-51. 2007
    ..Here we discuss these potential approaches with particular emphasis on the use of immune cells as carrier vehicles to deliver viral therapies to the tumor...
  2. ncbi request reprint Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects
    Stephen H Thorne
    Department of Pediatrics and Bio X Program, Stanford University School of Medicine, Stanford, CA 94305 5427, USA
    Semin Oncol 32:537-48. 2005
    ..The movement of these viruses into the clinic has begun to demonstrate the potential of this approach in the treatment of cancers...
  3. ncbi request reprint Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors
    Steve H Thorne
    Stanford University, Bio X Programme and Department of Pediatrics, Clark Center, California 94305, USA
    Expert Opin Biol Ther 7:41-51. 2007
    ....
  4. pmc Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
    Steve H Thorne
    Department of Pediatrics and Bio X Program, James H Clark Center, Stanford University School of Medicine, Stanford, California, USA
    J Clin Invest 117:3350-8. 2007
    ..JX-963 therefore holds promise as a rationally designed, targeted virotherapeutic for the systemic treatment of cancer in humans and warrants clinical testing...
  5. pmc CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy
    Steve H Thorne
    Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA
    Mol Cancer Ther 8:333-41. 2009
    ..This feature may simplify exploration of barriers to the penetration of MCHB in tumors and their amelioration...
  6. ncbi request reprint Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus
    Steve H Thorne
    Bio X Program, Dept of Pediatrics, School of Medicine, Stanford University, CA, USA
    Expert Opin Biol Ther 4:1307-21. 2004
    ....
  7. pmc Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killing
    Yoram Barak
    Department of Microbiology and Immunology, Sherman Fairchild Science Building, Stanford University School of Medicine, 299 Campus Drive, Stanford, CA 94305, USA
    BMC Cancer 10:146. 2010
    ..Whether NO generation by the bacteria has a role in SL7838 lethality to cancer cells is explored. This bacterium has the mechanism for generating NO, but also for decomposing it...
  8. ncbi request reprint Synergistic antitumor effects of immune cell-viral biotherapy
    Steve H Thorne
    Departments of Pediatrics, Radiology, Microbiology, and Immunology Stanford University School of Medicine, Stanford, CA 94305, USA
    Science 311:1780-4. 2006
    ..These results illustrate the potential of combining biotherapeutics for synergistic effects that more effectively treat cancer...
  9. ncbi request reprint Oncolytic vaccinia virus: from bedside to benchtop and back
    Steve H Thorne
    University of Pittsburgh Cancer Institute and Division of Surgical Oncology, Hillman Cancer Center, 5150 Centre Avenue, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Curr Opin Mol Ther 10:387-92. 2008
    ..Preclinical models incorporating new oncolytic vaccinia strains, as well as data from the first clinical trials that have utilized the next-generation oncolytic vaccinia strains for the potential treatment of cancer have been described...
  10. ncbi request reprint Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University, Stanford, California, USA
    Clin Cancer Res 12:1859-67. 2006
    ..Bispecific antibodies significantly enhanced the cytotoxicity of CIK cells in primary ovarian cancer cells and in our in vivo mouse model. The mechanism of cytolysis seems to be mediated in part by the NKG2D receptor...